The Supreme Court temporarily halted a lower court order that threatened to restrict access to mifepristone, the abortion pill used in medication abortions across the United States. The justices issued a brief order Thursday blocking enforcement of the lower court decision while they consider the case's merits in a future ruling.
Danco Laboratories, the drug's manufacturer, challenged the lower court order in Danco Laboratories v. Louisiana. The pharmaceutical company argued that restrictions on mifepristone lacked legal basis and would harm patients who rely on the medication.
This represents the second major Supreme Court intervention on mifepristone in recent years. The justices previously blocked a Trump-era Republican effort to revoke FDA approval of the drug in 2023. That earlier decision preserved the drug's availability nationwide, though it reflected deep ideological divisions within the Court.
The current reprieve remains temporary. The Supreme Court has not decided whether it will ultimately hear arguments in Danco Laboratories v. Louisiana or dismiss the case entirely. The stay keeps mifepristone accessible under existing FDA guidelines while litigation continues.
Abortion access has dominated Supreme Court dockets since the justices overturned Roe v. Wade in June 2022, eliminating the constitutional right to abortion. That decision shifted regulatory authority to individual states, spawning a patchwork of abortion bans and restrictions. Mifepristone battles have emerged as a central front in post-Dobbs abortion fights, with red states and anti-abortion groups pursuing legal challenges to the drug's approval or availability.
The pharmaceutical and medical communities have consistently defended mifepristone as safe and effective. The drug has been in use for over two decades with a strong safety record. Federal judges appointed by both Republican and Democratic presidents have previously rejected efforts to curtail its use.
The Court's indefinite block suggests the justices want to